Expanding Core Market Embecta is focusing on strengthening its core insulin delivery business through strategic reorganization and cost reductions, presenting opportunities to offer complementary device enhancements or integration solutions that support their core products.

Adjacent Market Growth The company's efforts to expand into drug delivery and chronic care segments open avenues for sales of innovative pharma partnerships, device accessories, and advanced delivery systems tailored to new markets.

Cost Optimization Initiatives Embecta's restructuring to reduce operational costs and debt creates an opportunity for suppliers of manufacturing efficiencies, automation tools, and cost-saving technologies to assist in their optimization efforts.

Technology Partnerships Their focus on leveraging new pharma collaborations suggests potential for joint development or integration of digital health platforms, data analytics, or sensor-based monitoring solutions to enhance their insulin delivery devices.

Market Trends Adaptation With shifting trends towards pump patches and GLP-1 therapies, Embecta is positioned to explore partnerships in advanced infusion systems, biosensing, and patient engagement platforms to address evolving treatment modalities.